Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.45 |
| ▸ | CES1 | P23141 | 1/20 | 0.45 |
| ▸ | P4HTM | Q9NXG6 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CCR1 | P32246 | 1/20 | 0.42 |
| ▸ | CCR5 | P51681 | 1/20 | 0.42 |
| ▸ | CCR8 | P51685 | 1/20 | 0.42 |
| ▸ | METAP1 | P53582 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL450118 | 0.84 | CES2 (0.46) | CES2CES1P4HTMLMNAL3MBTL1 | |
| SCHEMBL11865903 | 0.84 | CES2 (0.46) | CES2CES1P4HTMLMNAL3MBTL1 | |
| SCHEMBL28960343 | 0.83 | CES2 (0.45) | CES2CES1P4HTMLMNAL3MBTL1 | |
| SCHEMBL101751 | 0.83 | LMNA (0.48) | CES2CES1P4HTMLMNAL3MBTL1 | |
| SCHEMBL7351837 | 0.81 | CES2 (0.43) | CES2CES1P4HTMLMNAL3MBTL1 | |
| SCHEMBL519065 | 0.81 | CES2 (0.43) | CES2CES1P4HTMLMNAL3MBTL1 | |
| SCHEMBL253858 | 0.81 | CES2 (0.43) | CES2CES1P4HTMLMNAL3MBTL1 | |
| SCHEMBL2523378 | 0.81 | CES2 (0.43) | CES2CES1P4HTMLMNAL3MBTL1 | |
| SCHEMBL6243649 | 0.81 | CES2 (0.43) | CES2CES1P4HTMLMNAL3MBTL1 | |
| SCHEMBL7521569 | 0.81 | CES2 (0.48) | CES2CES1P4HTMLMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4371979-A1 | FORMAMIDE DERIVATIVE AND AGRICULTURAL OR HORTICULTURAL PLANT DISEASE CONTROL AGENT | Kumiai Chemical Industry Co., Ltd. (JP) | 2024-05-22 | — | — | EP | disclosed |
| CN-117693500-A | Carboxamide derivative and agricultural/horticultural plant disease control agent | 组合化学工业株式会社 | 2024-03-12 | — | — | CN | disclosed |
| WO-2023286855-A1 | FORMAMIDE DERIVATIVE AND AGRICULTURAL OR HORTICULTURAL PLANT DISEASE CONTROL AGENT | クミアイ化学工業株式会社 | 2023-01-19 | — | — | WO | disclosed |
| US-20120264678-A1 | METHODS OF USING [3.2.0] HETEROCYCLIC COMPOUNDS AND ANALOGS THEREOF FOR TREATING INFECTIOUS DISEASES | NEREUS PHARMACEUTICALS, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| US-20100168046-A1 | METHODS OF USING [3.2.0] HETEROCYCLIC COMPOUNDS AND ANALOGS THEREOF FOR TREATING INFECTIOUS DISEASES | NEREUS PHARMACEUTICALS, INC. (US) | 2010-07-01 | — | — | US | disclosed |
| WO-2008137780-A2 | USE OF [3.2.0] HETEROCYCLIC COMPOUNDS AND ANALOGS THEREOF FOR TREATING INFECTIOUS DISEASES | NEREUS PHARMACEUTICALS, INC. (US) | 2008-11-13 | — | — | WO | disclosed |
| US-20080280968-A1 | METHODS OF USING [3.2.0] HETEROCYCLIC COMPOUNDS AND ANALOGS THEREOF FOR TREATING INFECTIOUS DISEASES | NEREUS PHARMACEUTICALS, INC. (US) | 2008-11-13 | — | — | US | disclosed |
| WO-2008124699-A1 | A METHOD OF USING PROTEASOME INHIBITORS IN COMBINATION WITH HISTONE DEACETYLASE INHIBITORS TO TREAT CANCER | NEREUS PHARMACEUTICALS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264678-A1 | METHODS OF USING [3.2.0] HETEROCYCLIC COMPOUNDS AND ANALOGS THEREOF FOR TREATING INFECTIOUS DISEASES | GOT2, CYP11B2, CYP27A1 | CES2 37/4885CES1 93/4885P4HTM 1318/4885 |
| US-20100168046-A1 | METHODS OF USING [3.2.0] HETEROCYCLIC COMPOUNDS AND ANALOGS THEREOF FOR TREATING INFECTIOUS DISEASES | GOT2, CYP11B2, CYP27A1 | CES2 45/4885CES1 94/4885P4HTM 1283/4885 |
| US-20080280968-A1 | METHODS OF USING [3.2.0] HETEROCYCLIC COMPOUNDS AND ANALOGS THEREOF FOR TREATING INFECTIOUS DISEASES | GOT2, CYP11B2, CYP27A1 | CES2 45/4885CES1 94/4885P4HTM 1283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.